Banyan Capital Management Inc. increased its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 61.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 125,083 shares of the company’s stock after purchasing an additional 47,391 shares during the period. Henry Schein comprises about 4.8% of Banyan Capital Management Inc.’s investment portfolio, making the stock its 11th largest position. Banyan Capital Management Inc. owned about 0.10% of Henry Schein worth $8,018,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of HSIC. Summit Securities Group LLC acquired a new stake in Henry Schein during the second quarter valued at approximately $31,000. Beach Investment Counsel Inc. PA bought a new stake in shares of Henry Schein in the 2nd quarter worth about $37,000. Blue Trust Inc. boosted its position in Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock valued at $60,000 after buying an additional 475 shares in the last quarter. Mather Group LLC. bought a new position in shares of Henry Schein in the first quarter valued at approximately $97,000. Finally, Palisade Asset Management LLC acquired a new stake in Henry Schein during the 1st quarter valued at $113,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Trading Up 0.1 %
NASDAQ:HSIC opened at $72.54 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.55 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a twelve month low of $60.01 and a twelve month high of $82.63. The company has a market cap of $9.29 billion, a P/E ratio of 24.51, a price-to-earnings-growth ratio of 1.88 and a beta of 0.86. The business has a 50 day moving average price of $69.77 and a two-hundred day moving average price of $70.42.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on HSIC shares. Robert W. Baird lowered their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. Barrington Research decreased their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $86.00 price objective on shares of Henry Schein in a research report on Friday, June 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $77.10.
Check Out Our Latest Analysis on Henry Schein
Insider Activity at Henry Schein
In other news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.14% of the stock is currently owned by company insiders.
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading
- Five stocks we like better than Henry Schein
- Investing in Construction Stocks
- Roku Stock Gains New Buy Rating: Here’s Why Analysts Are Bullish
- Investing In Preferred Stock vs. Common Stock
- Prepare for a Silver Surge: Best Mining Stocks to Watch Now
- What is the Dogs of the Dow Strategy? Overview and Examples
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.